Literature DB >> 26070907

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer.

Tomoyoshi Takenaka1, Eiko Inamasu2, Tsukihisa Yoshida2, Gouji Toyokawa2, Kaname Nosaki2, Fumihiko Hirai2, Masafumi Yamaguchi2, Takashi Seto2, Mitsuhiro Takenoyama2, Yukito Ichinose2,3.   

Abstract

PURPOSE: The purpose of this study was to evaluate the outcomes of elderly patients 75 years of age or older with recurrent non-small cell lung cancer (NSCLC).
METHODS: A total of 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of these patients, 280 experienced postoperative recurrence. The rate of the post-recurrence survival and predictors were analyzed independently in a group of younger patients (<75 years) and a group of elderly patients (≥75 years).
RESULTS: There were 215 younger patients (<75 years) and 65 elderly (≥75 years) patients at the time of diagnosis of recurrence. The median post-recurrence survival time and the five-year survival rate of all cases were 25 months and 20.8%, respectively. There were no significant survival differences between the younger and elderly groups (p = 0.20). A univariate analysis determined that gender, Eastern Cooperative Oncology Group performance status, smoking status, histological type and epithelial growth factor receptor (EGFR) mutation status were factors influencing the post-recurrence survival among the elderly patients. In addition, a multivariate analysis determined the EGFR mutation status to be an independent prognostic factor for the post-recurrence survival.
CONCLUSIONS: Elderly patients 75 years of age or older in this study achieved satisfactory long-term outcomes.

Entities:  

Keywords:  Elderly patient; Non-small cell lung cancer; Post-recurrence survival; Postoperative recurrence; Surgical resection

Mesh:

Substances:

Year:  2015        PMID: 26070907     DOI: 10.1007/s00595-015-1200-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  21 in total

1.  Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis.

Authors:  Jung-Jyh Hung; Wen-Juei Jeng; Wen-Hu Hsu; Kou-Juey Wu; Teh-Ying Chou; Chih-Cheng Hsieh; Min-Hsiung Huang; Jung-Sen Liu; Yu-Chung Wu
Journal:  Thorax       Date:  2010-03       Impact factor: 9.139

2.  Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Authors:  Elisabeth Quoix; Gérard Zalcman; Jean-Philippe Oster; Virginie Westeel; Eric Pichon; Armelle Lavolé; Jérôme Dauba; Didier Debieuvre; Pierre-Jean Souquet; Laurence Bigay-Game; Eric Dansin; Michel Poudenx; Olivier Molinier; Fabien Vaylet; Denis Moro-Sibilot; Dominique Herman; Jaafar Bennouna; Jean Tredaniel; Alain Ducoloné; Marie-Paule Lebitasy; Laurence Baudrin; Silvy Laporte; Bernard Milleron
Journal:  Lancet       Date:  2011-08-08       Impact factor: 79.321

3.  Treatment of the postoperative recurrence of lung cancer in octogenarians.

Authors:  Manabu Yasuda; Akira Nagashima; Akira Haro; Genkichi Saitoh
Journal:  Surg Today       Date:  2013-09-12       Impact factor: 2.549

4.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

Authors:  Shinzoh Kudoh; Koji Takeda; Kazuhiko Nakagawa; Minoru Takada; Nobuyuki Katakami; Kaoru Matsui; Tetsu Shinkai; Toshiyuki Sawa; Isao Goto; Hiroshi Semba; Takashi Seto; Masahiko Ando; Taroh Satoh; Naruo Yoshimura; Shunichi Negoro; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

5.  Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.

Authors:  Makoto Sonobe; Tetsu Yamada; Masaaki Sato; Toshi Menju; Akihiro Aoyama; Toshihiko Sato; Fengshi Chen; Mitsugu Omasa; Toru Bando; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2014-03-17       Impact factor: 5.344

6.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients.

Authors:  Brent A Williams; Hiroshi Sugimura; Chiaki Endo; Francis C Nichols; Stephen D Cassivi; Mark S Allen; Peter C Pairolero; Claude Deschamps; Ping Yang
Journal:  Ann Thorac Surg       Date:  2006-03       Impact factor: 4.330

9.  First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

Authors:  Akira Inoue; Kunihiko Kobayashi; Kazuhiro Usui; Makoto Maemondo; Shoji Okinaga; Iwao Mikami; Masahiro Ando; Koichi Yamazaki; Yasuo Saijo; Akihiko Gemma; Hitoshi Miyazawa; Tomoaki Tanaka; Kenji Ikebuchi; Toshihiro Nukiwa; Satoshi Morita; Koichi Hagiwara
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

10.  Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.

Authors:  Tomoyoshi Takenaka; Mitsuhiro Takenoyama; Masafumi Yamaguchi; Ryo Toyozawa; Eiko Inamasu; Miyako Kojo; Gouji Toyokawa; Tsukihisa Yoshida; Yoshimasa Shiraishi; Yosuke Morodomi; Fumihiko Hirai; Kenichi Taguchi; Mototsugu Shimokawa; Takashi Seto; Yukito Ichinose
Journal:  Eur J Cardiothorac Surg       Date:  2014-06-03       Impact factor: 4.191

View more
  5 in total

1.  Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer.

Authors:  Yasuaki Kubouchi; Yoshiteru Kidokoro; Takashi Ohno; Yohei Yurugi; Makoto Wakahara; Tomohiro Haruki; Hiroshige Nakamura
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

2.  Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

Authors:  Alfonso Fiorelli; Francesco Paolo Caronia; Niccolò Daddi; Domenico Loizzi; Luca Ampollini; Nicoletta Ardò; Luigi Ventura; Paolo Carbognani; Rossella Potenza; Francesco Ardissone; Francesco Sollitto; Sandro Mattioli; Francesco Puma; Mario Santini; Mark Ragusa
Journal:  Surg Today       Date:  2016-04-16       Impact factor: 2.549

3.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.

Authors:  Ting-Yuan David Cheng; Susanna M Cramb; Peter D Baade; Danny R Youlden; Chukwumere Nwogu; Mary E Reid
Journal:  J Thorac Oncol       Date:  2016-06-27       Impact factor: 15.609

4.  Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer.

Authors:  Shinkichi Takamori; Mototsugu Shimokawa; Taichi Matsubara; Naoki Haratake; Ryo Toyozawa; Naoko Miura; Masafumi Yamaguchi; Takashi Seto; Tetsuzo Tagawa; Tatsuro Okamoto; Mitsuhiro Takenoyama; Yoshihiko Maehara; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2020-07-16       Impact factor: 5.344

5.  Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old.

Authors:  Guannan Wu; Xiaoling Gu; Dongmei Yuan; Yanwen Yao; Wen Yang; Tangfeng Lv; Yong Song
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.